← Back to Search

Selective Serotonin Reuptake Inhibitor

B for Depression (iSPOT-D Trial)

Phase 4
Waitlist Available
Led By Radu V Saveanu, MD
Research Sponsored by BRC Operations Pty. Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52-weeks
Awards & highlights

iSPOT-D Trial Summary

The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine, Sertraline) in patients diagnosed with major depressive disorder. This study is focused on outcomes which may impact on how "personalised medicine" is implemented in depression.

Eligible Conditions
  • Depression

iSPOT-D Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52-weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52-weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalise' with acute drug treatment in MDD
Secondary outcome measures
To determine whether markers of acute treatment prediction are also predictive of functional outcome over 6-12 months.

iSPOT-D Trial Design

4Treatment groups
Active Control
Group I: BActive Control1 Intervention
Sertraline
Group II: DActive Control1 Intervention
Healthy matched controls
Group III: CActive Control1 Intervention
Venlafaxine-XR
Group IV: AActive Control1 Intervention
Escitalopram

Find a Location

Who is running the clinical trial?

BRC Operations Pty. Ltd.Lead Sponsor
1 Previous Clinical Trials
1,344 Total Patients Enrolled
Radu V Saveanu, MDPrincipal InvestigatorUniversity of Miami
Anthony Harris, MDPrincipal InvestigatorBrain Dynamics Centre

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Biological PsychiatryJournal
Abnormal Structural Networks Characterize Major Depressive Disorder: A Connectome Analysis
Korgaonkar, Mayuresh S., Alex Fornito, Leanne M. Williams, and Stuart M. Grieve. 2014. “Abnormal Structural Networks Characterize Major Depressive Disorder: A Connectome Analysis”. Biological Psychiatry. Elsevier BV. doi:10.1016/j.biopsych.2014.02.018.
clinicaltrials.govStudy
International Study to Predict Optimised Treatment - in Depression
2008. "International Study to Predict Optimised Treatment - in Depression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00693849.
All > Effexor
~162 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top